Showing results (31-40 of 270) with videos related to
Sort By:
Pageof 27
Critical Reviews in Oncology/Hematology|September 8, 2025
Optimizing management of cutaneous toxicities from amivantamab in first-line non-small cell lung cancer: A clinical perspectiveIlaria Attili, Giulio Tosti, Francesca Pepe, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2024
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief ReportDaniele Tavernari, Maxime Borgeaud, Ximeng Liu, et al.Current Oncology (Toronto, Ont.)|January 20, 2022
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available EvidenceIlaria Attili, Antonio Passaro, Pasquale Pisapia, et al.Cancer Treatment Reviews|July 30, 2025
Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerPaul K Paik, Wade T Iams, Hatim Husain, et al.Targeted Oncology|May 6, 2026
Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature ReviewKoichi Goto, Hidetoshi Hayashi, Sonia S Maruti, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2024
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic ReviewMaxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2022
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer TherapySonia A Patel, Monique B Nilsson, Xiuning Le, et al.Lung Cancer (Amsterdam, Netherlands)|March 8, 2021
Strategies to overcome resistance to immune checkpoint blockade in lung cancerIlaria Attili, Paolo Tarantino, Antonio Passaro, et al.Critical Reviews in Oncology/Hematology|October 26, 2017
Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?Ilaria Attili, Antonio Passaro, Alberto Pavan, et al.Clinical Lung Cancer|June 6, 2020
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint InhibitorsAlex Friedlaender, Stephen V Liu, Antonio Passaro, et al.Pageof 27